Stocks of Zomedica Corp (AMEX:ZOM) traded higher last session on Wall Street, down -2.27% to $0.17.
According to the data, Zomedica Corp (AMEX:ZOM) has 1 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $0.44 and a low of $0.44, we find $0.44. Given the previous closing price of $0.17, this indicates a potential upside of 158.82 percent. ZOM stock price is now -1.78% away from the 50-day moving average and -17.60% away from the 200-day moving average. The market capitalization of the company currently stands at $164.73M.
A total of 1 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $0.44 as their price target over the next twelve months.
With the price target of $6, Dawson James recently initiated with Buy rating for Zomedica Corp (AMEX: ZOM).
In other news, HEATON LARRY C II, CEO bought 100,000 shares of the company’s stock on May 26. The stock was bought for $19,090 at an average price of $0.19. Upon completion of the transaction, the CEO now directly owns 100,000 shares in the company, valued at $17000.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 25, Director POWERS JOHNNY D bought 100,000 shares of the business’s stock. A total of $19,340 was incurred on buying the stock at an average price of $0.19. This leaves the insider owning 1,600,000 shares of the company worth $0.27 million. A total of 1.55% of the company’s stock is owned by insiders.
Wednesday’s opening bell rang with an opening price of $0.1691 for Zomedica Corp (AMEX: ZOM). During the past 12 months, Zomedica Corp has had a low of $0.15 and a high of $0.34. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 17.12, and a quick ratio of 16.57. The fifty day moving average price for ZOM is $0.1712 and a two-hundred day moving average price translates $0.2041 for the stock.
The latest earnings results from Zomedica Corp (AMEX: ZOM) was released for Sep, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0, inline with analysts’ expectations of $0. This compares to -$0.01 EPS in the same period last year. The net profit margin was -62.21% and return on equity was -5.64% for ZOM. The company reported revenue of $6.35 million for the quarter, compared to $4.78 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.89 percent. For the current quarter, analysts expect ZOM to generate $10.81M in revenue.